UBS Knock-Out AMGN/ DE000UH2GKP6 /
03/05/2024 19:26:47 | Chg.+0.350 | Bid21:56:58 | Ask21:56:58 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.950EUR | +58.33% | - Bid Size: - |
- Ask Size: - |
Amgen Inc | 211.4139 USD | 31/12/2078 | Call |
GlobeNewswire
02/05
Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Canc...
GlobeNewswire
01/05
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Su...
GlobeNewswire
01/05
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clin...
GlobeNewswire
30/04
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab bios...
GlobeNewswire
24/04
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeti...
GlobeNewswire
23/04
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
15/04
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
GlobeNewswire
15/04
Shah Capital nominates two highly qualified independent director candidates for Novavax
GlobeNewswire
08/04
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual ...
GlobeNewswire
08/04
CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Dire...